{"id":"W3089292170","doi":"10.1016/j.annonc.2020.08.2088","title":"694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"Genentech; EUSA Pharma; Ipsen; Astellas Pharma; Eisai; Sanofi; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Docetaxel; Tolerability; Oncology; Antiandrogen; Hazard ratio; Randomized controlled trial; Urology; Cancer; Adverse effect; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001165976,0.001439483,0.00231035,0.0006024127,0.0003767065,0.0009515614,0.001298205,0.001516522,0.01440792],"category_scores_gemma":[0.001101007,0.0006968075,0.001522675,0.0004902668,0.001025996,0.0007752248,0.000484245,0.003487734,0.00152127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005278682,"about_ca_system_score_gemma":0.00107392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001301137,"about_ca_topic_score_gemma":0.002676231,"domain_scores_codex":[0.9995468,0.0002502273,0.00002094381,0.00006282132,0.00003752602,0.00008162607],"domain_scores_gemma":[0.9994525,0.0001760049,0.00007516326,0.00003888004,0.00003200821,0.0002253358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9536256,0.007188505,0.0002296634,0.0009691866,0.0008850056,0.00003138221,0.00003368153,0.0003752807,0.004202075,0.00015812,0.001529074,0.03077252],"study_design_scores_gemma":[0.8728465,0.1230494,0.001344277,0.00004444563,0.0003821201,0.00004054041,0.00001906958,0.0003364598,0.0007655442,0.00009248357,0.001061294,0.00001789348],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719172,0.01442729,0.000620849,0.0007302747,0.001071268,0.003131164,0.001652461,0.0004029867,0.006046588],"genre_scores_gemma":[0.9812545,0.006261515,0.001377477,0.0008269182,0.0005428138,0.002159792,0.001534232,0.00003988076,0.006002874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01440792,"threshold_uncertainty_score":0.04819936,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.118037243777001,"score_gpt":0.4164679729252467,"score_spread":0.2984307291482456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}